Applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis

A technology of atherosclerosis and cordycepin, which is applied in the field of cordycepin, can solve the problems of insufficient confirmation of cordycepin and no cholesterol, and achieve the effects of avoiding atherosclerotic plaque, improving antioxidant capacity, and reducing deposition

Inactive Publication Date: 2014-07-02
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the animal model of balloon injury mainly simulates the arterial injury and plaque formation of blood vessels under mechanical stress, which is quite different from the natural AS pathogenesis and process of humans, so their data are not yet sufficient to confirm the effect of cordycepin on naturally occurring , especially for the treatment of AS due to obesity and hyperlipidemia
In addition, inhibiting the formation of oxLDL and regulating the influx and efflux of cholesterol in macrophages has been recognized as an important target for the prevention and treatment of AS. Cholesterol uptake by cells and promotion of cholesterol efflux from macrophages reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis
  • Applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis
  • Applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Cordycepin reduces plaque formation in the aorta of ApoE- / - atherosclerosis model mice

[0023] Get 8 weeks old Apo E- / - mice 32, divide into model group, simvastatin positive group (20mg / kg) at random, cordycepin low (25mg / kg) and high (50mg / kg) dosage group (each group 8). All groups were fed with high-fat feed, and the corresponding drugs were given by intragastric administration at the same time, and the hyperlipidemia model group was intragastrically administered with the same volume of tap water. After 24 weeks of administration, HE staining was used to observe the percentage of atherosclerotic plaque area and vascular lumen area in the aortic root to evaluate the pharmacodynamic effect of cordycepin against arteriosclerosis.

[0024] After 24 weeks of high-fat diet feeding, atherosclerotic plaques appeared in the aortic roots of the animals in the model group, and the percentage of the area of ​​atherosclerotic plaques to the area of ​​the vascular lum...

Embodiment 2

[0025] Example 2 Cordycepin reduces serum cholesterol and triglyceride levels in an animal model of hyperlipidemia (golden hamster)

[0026] Get 60 80-100g male golden hamsters and randomly divide them into normal group, hyperlipidemia model group, fenofibrate positive control group (40mg / kg) and 3 dosage groups of cordycepin (doses are respectively 12.5, 25 and 50mg / kg). kg) in a total of 6 groups (10 in each group). The normal group was fed with standard feed, the rest of the groups were fed with high-fat feed, and the corresponding drugs were given by intragastric administration, and the hyperlipidemia model group was intragastrically administered with the same volume of tap water. After 4 weeks of dosing, animals were fasted for 8 hours, sacrificed and blood samples collected for assessment of serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c) and high-density lipoprotein (HDL-c).

[0027] After treating hyperlipidemic animal models with co...

Embodiment 3

[0031] Example 3 Cordycepin improves the oxidative stress in the animal model of hyperlipidemia (golden hamster)

[0032] After treating hyperlipidemic animal models with cordycepin for 4 weeks, serum total antioxidant capacity kit, superoxide dismutase (SOD) activity assay kit, catalase (CAT) activity assay kit and malondialdehyde (MDA) content assay kit measures the total antioxidant capacity, CAT and SOD activities and MDA content in animal serum. It was found that intragastric administration of cordycepin can significantly improve the peroxidation state of animals, increase serum total antioxidant capacity and superoxide dismutase (SOD) activity, and significantly reduce serum MDA content. At the dose of 25mg / kg, the effect has been more significant ( figure 2 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to medical novel applications of cordycepin (3'-deoxyadenosine), and more specifically relates to applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis and atherosclerosis related diseases. It is confirmed by pharmacodynamic experiments that: cordycepin is capable of inhibiting formation of ApoE-/- mice aorta atherosclerotic plaques significantly, reducing serum TC, TG, and LDL-c contents of animals with hyperlipidemia, increasing total antioxidant capacity and SOD activity of animal serum, reducing MDA content, reducing contents of serum interleukin 2 and interleukin 8 significantly, and inhibiting inflammation. It is confirmed by cell experiments that: cordycepin is capable of inhibiting uptake of mononuclear cell RAW267.4 on cholesterol significantly, and promoting flowing of cholesterol out from cells.

Description

technical field [0001] The invention relates to a new medical application of cordycepin (3'-deoxyadenosine) which is a single component in the extract of Cordyceps militaris. It specifically relates to the use of cordycepin for preparing medicines for preventing and treating atherosclerosis and diseases related to atherosclerosis. Background technique [0002] With the progress of society and the change of lifestyle, the incidence of cardiovascular diseases such as atherosclerosis is increasing year by year. Studies have shown that atherosclerosis is a systemic disease related to lipid metabolism disorders. Its lesion is characterized by the deposition of lipids in the blood, especially cholesterol, in the intima of the arterial wall to form atherosclerotic plaques, leading to arteriosclerosis. . When atherosclerosis occurs in important organs such as the heart and brain, it will cause tissue ischemic changes and cause serious consequences, such as angina pectoris, myocard...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7076A61P9/10A61P3/06A61P39/06A61P29/00
Inventor 郭鹏吴崇明朱平张雪栾虹
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap